Contrasting time- And rate-based approaches for the assessment of drug-induced QThanges

Journal of Clinical Pharmacology

Volumn 47, Issue 9, 2007, Pages 1129-1137

  Extramiana, Fabrice ^a   Badilini, Fabio ^b   Sarapa, Nenad ^c   Leenhardt, Antoine ^a   Maison Blanche, Pierre ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

^b AMPS LLC   (United States)

^c DAIICHI SANKYO INC   (United States)

Author keywords

Holier ECG; QT interval; Sotalol

Indexed keywords

PLACEBO; SOTALOL;

ADULT; ARTICLE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; DATA ANALYSIS; FEMALE; HEART RATE; HOLTER MONITORING; HUMAN; INTERMETHOD COMPARISON; MALE; NORMAL HUMAN; OPEN STUDY; QRS COMPLEX; QT INTERVAL; QT PROLONGATION; RR INTERVAL; SINGLE DRUG DOSE;

ADULT; ANTI-ARRHYTHMIA AGENTS; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HEART RATE; HUMANS; LONG QT SYNDROME; MALE; MODELS, CARDIOVASCULAR; SOTALOL; TIME FACTORS;

EID: 40049091488     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007302953     Document Type: Article

References (38)

1. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J. Med. 2004;351:1089-1096.
2. 2. Crouch MA, Limon L, Cassano AT. Clinical relevance and management of drug-related QT interval prolongation. Pharmacotherapy. 2003;23:881-908. (Pubitemid 36875672)
3. 3. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and Torsade de Pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003;58:32-45. (Pubitemid 36351620)
4. Vos MA, van Opstal JM, Leunissen JD, Verduyn SC. Electrophysiologic parameters and predisposing factors in the generation of drug-induced Torsade de Pointes arrhythmias. Pharmacol Ther. 2001;92:109-122.
5. 5. Curtis LH, Ostbye T, Sendersky V, et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med. 2003;114:135-141. (Pubitemid 36183596)
6. 6. Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf. 2001;24:323-351. (Pubitemid 32417533)
7. International Conference on Harmonization (ICH). E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Available at: http://www .fda.gov/cder/guidance/ 6922fnl.pdf. Accessed August 21, 2006.
8. Shah RR. Drugs, QTc interval prolongation and final ICH E14 guideline: an important milestone with challenges ahead. Drug Saf. 2005;28:1009-1028.
9. Bazett HC. An analysis of the time relationship of electrocardiograms. Heart. 1920;7:353-370.
10. 10, Franz MR, Swerdlow CD, Liem LB, Schaefer J. Cycle length dependence of human action potential duration in vivo: effects of single extrastimuli, sudden sustained rate acceleration and deceleration, and different steady state frequency. J Clin Invest. 1988; 82:972-979. (Pubitemid 18228356)
11. Browne KF, Prystowsky E, Heger JJ, Chilson DA, Zipes DP. Prolongation of the QT interval in man during sleep. Am J. Cardiol. 1983;52:55-59.
12. Rautaharju PM, Zhou SH, Wong S, et al. Sex differences in the evolution of the electrocardiographic QT interval with age. Can J. Cardiol. 1992;8:690-695.
13. 13, Bexton R, Vallin HO, Camm AJ. Diurnal variation of the QT interval-influence of the autonomic nervous system. Br Heart J. 1986;55:253-258. (Pubitemid 16137868)
14. Food and Drug Administration. Critical Path Initiative. Innovation or Stagnation? Challenge and Opportunity on the Critical Path to New Medical Pmducts 2004. Available at: http://www.fda.gov.
15. 15, Malik M, Farbom P, Batchvarov V, Hnatkova K, Camm AJ. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart. 2002;87:220-228. (Pubitemid 34177674)
16. Rautaharju PM, Zhang ZM. Linearly scaled, rate-invariant normal limits for QT interval: eight decades of incorrect application of power functions. J. Cardiovasc Electrophysiol. 2002;13:1211-1218.
17. 17, Extramiana F, Maison-Blanche P, Cabanis MJ, OrtemannRenon C, Beaufils P, Leenhardt A. Clinical assessment of druginduced QT prolongation when associated with heart rate changes. Clin Pharmacol Ther. 2005;77:247-258. (Pubitemid 40470381)
18. 18, Indik JH, Pearson EC, Fried K, Woosley RL. Bazett and Fridericia QT correction formulae interfere with measurement of drug-induced changes in QT interval. Heart Rhythm. 2006;3:1003-1007. (Pubitemid 44283697)
19. 19, Malik M. Assessment of drug-induced QT prolongation: to bin or not to bin? Clin Pharmacol Ther. 2005;77:241-246. (Pubitemid 40470380)
20. 20, Sarapa N, Morganroth J, Couderc JP, et al. Electrocardiographic identification of drug-induced QT prolongation: assessment by different recording and measurement methods. Ann Noninvasive Electrocardiol. 2004;9:48-57. (Pubitemid 38230430)
21. 21, Badilini F, Maison-Blanche P, Childers R, Coumel P. QT interval analysis on ambulatory electrocardiogram recordings: a selective beat averaging approach. Med Biol Eng Comput. 1999;37:71-79. (Pubitemid 129505697)
22. Badilini F, Maison-Blanche P. Holter monitoring for QT: the RR bin method in depth. In: Morganroth J, Gussak I, eds. Cardiac Safety of Noncardiac Drugs: Practical Guidelines for Clinical Research and Drug Development. Totowa, NJ: Humana; 2004.
23. 23, Extramiana F, Seitz J, Maison-Blanche P, et al. Quantitative assessment of ST segment elevation in Brugada patients. Heart Rhythm. 2006;3:1175-1181. (Pubitemid 44464146)
24. 24. Extramiana F, Maison-Blanche P, Haggui A, Badilini F, Beaufils P, Leenhardt A. Control of rapid heart rate changes for ECG analysis: implications for thorough QT studies. Clin Cardiol. 2006;29:534-539. (Pubitemid 44914781)
25. 25. Yi G, Guo XH, Reardon M, et al. Circadian variation of the QT interval in patients with sudden cardiac death after myocardial infarction. Am J Cardiol. 1998;81:950-956. (Pubitemid 28183658)
26. Funck-Brentano C, Jaillon P. Rate-corrected QT interval: techniques and limitations. Am J. Cardiol. 1993;72:17B-22B.
27. 27. Malik M. Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol. 2001;12:411-420. (Pubitemid 32324653)
28. Hnatkova K, Malik M. "Optimum" formulae for heart rate correction of the QT interval. PACE. 1999;22:1683-1687.
29. 29. Malik M. The imprecision in heart rate correction may lead to artificial observations of drug-induced QT interval changes. PACE. 2002;25:209-216. (Pubitemid 34214594)
30. 30. Lande G, Maison-Blanche P, Fayn J, Ghadanfar M, Coumel P, Funck-Brentano C. Dynamic analysis of dofetilide-induced changes in ventricular repolarization. Clin Pharmacol Ther. 1998; 64:312-321. (Pubitemid 28462292)
31. Funck-Brentano C, Kibleur Y, Le Coz F, Poirier JM, Mallet A, Jaillon P. Rate dependence of sotalol-induced prolongation of ventricular repolarization during exercise in humans. Circulation. 1991;83:536-545.
32. Viitasalo M, Karjalainen J. QT Intervals at heart rates from 50 to 120 beats per minutes during 24-hour electrocardiographic recordings in 100 healthy men. Circulation. 1992;86:1439-1442.
33. Extramiana F, Maison-Blanche P, Badilini F, Pinoteau J, Deseo T, Coumel P. Circadian modulation of QT rate dependence in healthy volunteers. J. Electrocardiol. 1999;32:33-43.
34. 34. Couderc JP, Xiaojuan X, Zareba W, Moss AJ. Assessment of the stability of the individual-based correction of QT interval for heart rate. Ann Noninvasive Electrocardiol. 2005;10:25-34. (Pubitemid 40476663)
35. 35. Extramiana F, Neyroud N, Huikuri HV, Koistinen MJ, Coumel P, Maison-Blanche P. QT interval and arrhythmic risk assessment after myocardial infarction. Am J Cardiol. 1999;83:266-269. (Pubitemid 29047311)
36. 36. Extramiana F, Maison-Blanche P, Tavernier R, Jordaens L, Leenhardt A, Coumel P. Cardiac effects of chronic oral beta-blockade: lack of agreement between heart rate and QT interval changes. Ann Noninvasive Electrocardiol. 2002;7:379-388. (Pubitemid 35370468)
37. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go: reduced effectiveness and dangers of reverse use dependence. Circulation. 1990;81: 686-690.
38. 38. Extramiana F, Maison-Blanche P, Badilini F, Beaufils P, Leenhardt A. Individual QT/RR relationship: average stability over time does not rule out an individual residual variability. Implication for the assessment of drug effect on the QT interval. Ann Noninv Electmcard. 2005;10:169-178. (Pubitemid 40646658)